Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis.

For example, remdesivir’s impact on mortality reported by the WHO in the SOLIDARITY publication did not reach statistical significance in the overall population 10 .

also in 111,027 other papers

However, in the subgroup of patients with low- and high-flow supplemental oxygen/non-mechanical ventilation, there was a numerical trend towards benefit of treatment with remdesivir, with 28-day mortality lower among those treated with remdesivir (9.4%) versus standard of care (10.6%) 10 .

also in 1,012 other papers